Canada markets closed

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5300+0.0200 (+1.32%)
At close: 04:00PM EDT
1.5800 +0.05 (+3.27%)
After hours: 06:23PM EDT

Frequency Therapeutics, Inc.

75 Hayden Avenue
Suite 300
Lexington, MA 02421
United States
781 315 4600
https://www.frequencytx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. David L. LucchinoCo-Founder, Pres, CEO & Director938.5kN/A1969
Dr. Carl P. LeBel Ph.D.Chief Devel. Officer633.4kN/A1959
Dr. Quentin McCubbin Ph.D.Chief Manufacturing Officer572.3kN/A1970
Dr. Christopher R. Loose Ph.D.Co­-Founder & Chief Scientific OfficerN/AN/A1981
Mr. James P. AbelyAssociate Gen. Counsel & Sec.N/AN/AN/A
Ms. Wendy S. ArnoldChief People OfficerN/AN/A1972
Dr. Dana C. Hilt M.D.Chief Medical OfficerN/AN/A1953
Dr. John L. LaMattina Ph.D.Sr. Advisor & Member of PCA Regenerative Medicine Advisory BoardN/AN/A1950
Dr. William W. Chin M.D.Sr. VP of Translational MedicineN/AN/A1948
Mr. Jason GlashowSr. VP of Corp. AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Frequency Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.